Schonfeld Strategic Advisors’s Gain Therapeutics GANX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.5K	Buy	+24,500	New	+$53.3K	﹤0.01%	1973

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Schonfeld Strategic Advisors's GANX Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Gain Therapeutics (GANX) in Q1 2026: 24,500 shares worth $47.5K. The stake represents ﹤0.01% of the portfolio and ranks #1973 among its holdings.

42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Schonfeld Strategic Advisors held 24,500 shares of Gain Therapeutics worth $47.5K as of Q1 2026.
Gain Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
Gain Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1973 holding.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.